AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2020
Oct 2, 2020
35172_dirs_2020-10-02_7122b55c-4349-4f3d-b0da-a7b319a16c27.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2020-10-02
Reporting Person: Lin Patrick (Chief Business - Strategy Off)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 368487 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (Right to buy) | $16.80 | 2024-06-20 | Common Stock (7859) | Direct | |
| Stock Options (Right to buy) | $16.80 | 2024-06-20 | Common Stock (8664) | Direct | |
| Warrants (Right to Buy) | $19.068 | 2021-06-29 | Common Stock (4469) | Direct |
Footnotes
F1: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F2: Stock options vest upon meeting certain performance criteria.
F3: Need warrant info here.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15